

MITHRA IS MEETING U.S. INSTITUTIONAL INVESTORS AT J.P. MORGAN CONFERENCE

Liège, Belgium - Mithra Pharmaceuticals, leader in Women's Health and cutting-edge technological company in the field of API slow-release drugs based on polymere (subcutaneous implants, biocompatible rings, hormonal IUD's), announced today its participation to the 34th edition of the annual J.P. Morgan Healthcare Conference which is held from 11 to 15 January 2016 in San Francisco.

Steven Peters, CFO of Mithra Pharmaceuticals: « 6 months elapsed since the listing of Mithra on Euronext Brussels. Our Initial Public Offering has been the largest IPO in the pharmaceutical sector on the Euronext markets for the last 10 years and the third largest IPO on the Euronext markets in 2015. Ultimately, Mithra raised EUR 79,3 million during the IPO and these proceeds make us confident on the financing of the development programs, mainly Estetrol for contraception and menopause, until end of phase III. This trust placed in us by the european investors, we try to get also from large US based institutional investors. The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference in biotech and pharmaceutical sectors and is a unique opportunity to share our strategic vision and our on-going development programs to a broad range of US-based analysts and institutional investors ».

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO/ Steven Peters, CFO/ Julie Dessart, CCO/ Jean-Manuel Fontaine, PRO

+32 4 349 28 22

investorrelations@mithra.com

To subscribe to Mithra's newsletter, visit investors.mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.